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Abstract
Background: There is a high prevalence of overweight and obesity in persons with severe mental disorders and
this has serious implications on the short and long term health outcomes of these patients. The aim of this review
was to evaluate the effectiveness of lifestyle interventions targeting physical activity and eating habits in persons
with severe mental disorders. Special attention was given if any of the included studies in the review also
examined the cost-effectiveness of these health promotion interventions.
Methods: A systematic search through the electronic databases Medline, Web of Science, CINAHL and Cohrane
Library was conducted, and by hand-searching the reference lists of the retrieved articles from the electronic
databases. Studies were included if they examined effectiveness and/or cost-effectiveness of lifestyle interventions
targeting physical activity and eating habits in persons with severe mental disorders, with primary outcome
changes in Body Mass Index and body weight.
Results: Fourteen studies met the inclusion criteria. Weight loss and Body Mass Index decrease were observed in
intervention groups in 11 studies. The difference in weight change between intervention and control groups was
statistically significant in nine studies. Differences in mean Body Mass Index between intervention and control
groups were statistically significant in eight studies. Five studies reported improvements in quality of life and
general health. In none of the studies cost-effectiveness of lifestyle interventions was examined.
Conclusion: Further research on both effectiveness and cost-effectiveness of lifestyle interventions targeting
physical activity and eating habits in persons with severe mental disorders is required to assist in the development
of new health promotion interventions in this population.
Introduction
Overweight (Body Mass Index 25-29 kg/m
2) and obesity
(Body Mass Index >30 kg/m
2) have become a serious
global public health problem, and the prevalence of obe-
sity is rapidly increasing [1]. Obesity is associated with
lifestyle factors such as sedentary lifestyles and poor
dietary choices [2,3] which contribute to major non
communicable diseases, including cardiovascular disease
(CVD), type 2 diabetes and certain types of cancer [4].
The burden of overweight and obesity is also increasing
in low- and middle-income countries [5]. Where in the
past obesity was mostly associated with the higher
socioeconomic groups, now tends to shift towards the
groups with lower socioeconomic status. In developing
countries, the underprivileged people living in urban
areas are especially affected by overweight and obesity
[6].
Growing attention is given to the effects of ‘healthy
living interventions’ targeting physical activity (PA) and
eating habits. In the general population, the effectiveness
of such interventions is already well established [7-9].
However, research on cost-effectiveness of ‘healthy living
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results of some studies suggest that specific lifestyle
interventions for specific target groups are cost-effective
[10-12]. Contrary, based on a systematic review, the
authors concluded that there is currently no sufficient
evidence to reliably compare cost-effectiveness results of
individual studies and that the generalization of pre-
sented findings is restricted considerably [13].
In people with severe mental disorders (SMD) the pre-
valence of obesity is higher than in the general popula-
tion [14,15]. Moreover, some studies provide evidence
of differences in rates of overweight and obesity when
gender is considered. In a study of the prevalence of
overweight and obesity in bipolar patients, the results
indicated that, in women with bipolar disorders, over-
weight and obesity were significantly more frequent,
compared to reference women. In men, only rates of
obesity were greater in patients than in reference sub-
jects but rates of overweight were not [16]. In a study of
169 patients with schizophrenia or major mood disor-
der, 17.0% of women had Body Mass Index (BMI) in the
o b e s eI I Ir a n g e( B M I> 4 0k g / m
2), compared with only
4.0% in the general population. Among the male
patients, 5.0% had BMI in the obese III range, compared
with 2.0% in the general population [17].
In people with SMD, it is important to note that some
atypical antipsychotics also have been associated with
weight gain. The degree of weight gain can vary accord-
ing to the type of antipsychotic medication [18].
Beside the higher prevalence of overweight and obe-
sity, people with SMD also have more sedentary life-
styles, including less moderate to vigorous PA [19,20],
and make poorer dietary choices, compared with the
general population. Poor dietary choices include eating
less frequently food recommended for large consump-
tion (e.g. fresh fruit, vegetables, wholegrain bread, rice)
and more instant meals [21-23] and fat [19] and having
less variety of food in their diet [24,25].
Despite these negative conditions, patients suffering
from SMD are less likely having their physical illnesses
diagnosed and managed effectively. Barriers to effective
physical healthcare include patient-related elements
(poor treatment compliance, treatment refusal), the nat-
ure of the illness (social isolation and suspicion, physical
symptoms unreported or masked because of high pain
tolerance in some patients associated with the use of
antipsychotics), physicians’ attention principally focused
on patients’ psychiatric problems and physical complaints
regarded as psychosomatic symptoms [26-29]. There is
limited evidence describing that the presence of a MD
does not affect the quality of physical health care. For
example, no differences in quality of diabetes care were
found between patients with schizophrenia or bipolar
disorder and patients with diabetes without MD [30].
This raises even more concern given an increased risk
of premature death in this population in comparison
with the general population [26,31]. Premature mortality
can be expressed by measuring the “years of potential
life lost” (YPLL). The YPLL is based on the current
mean survival age for a living cohort by age and by gen-
der [32]. YPLL among persons with MD are described
in several studies. In a study among 608 patients with
MD, the mean YPLL for all causes was 32 years [33].
The results of a recent study identified a mean YPLL of
14.5 years in persons with MD compared with 10.3
years for the general population [34]. The risk of prema-
ture death can also be assessed by calculating the stan-
dardized mortality ratio (SMI). For example, in a
retrospective cohort study, a SMI of 3.7 for patients
with MD was found compared with the general popula-
tion [35]. Respiratory disease, CVD and cancer are
important causes of this premature mortality in addition
to suicide [36-38]. As mentioned above, sedentary life-
styles and poor dietary choices are important risk factors
for these non communicable diseases.
Therefore, people with SMD require careful baseline
assessment and ongoing monitoring of physical health
parameters [39]. The treatment and prevention strate-
gies should include encouraging healthy lifestyles, smok-
ing cessation, appropriate diets and levels of activity,
with contribution of both mental health professionals
and primary care providers [14,40,41]. The European
Psychiatric Association stated that maintaining a healthy
body weight and shape by healthy eating and regular PA
is a key component in order to reduce the risk of some
important somatic diseases such as CVD and to improve
the overall health and well-being of patients [42].
The aim of this review was to evaluate the effects on
weight, BMI and quality of life (QOL) of lifestyle inter-
ventions targeting PA and eating habits in persons with
SMD. Special attention was given if any of the included
studies in the review also examined the cost-effective-
ness of these health promotion interventions.
Methods
Initially, the following electronic databases were
searched for the period 01-03-1990 until 01-03-2010:
Medline, Web of Science, CINAHL and Cohrane Library
using the search string ‘(Mental Disorders [MeSH] OR
Severe Mental Illness OR Antipsychotic Agents [MeSH])
AND (Obesity [MeSH] OR Weight Gain [MeSH] OR
Weight) AND (Lifestyle OR Intervention Studies
[MeSH] OR Food Habits [MeSH] OR Physical Activity
OR Fruit [MeSH] OR Vegetables [MeSH])’. The search
was limited to randomized controlled trials, clinical
trials, reviews and meta-analysis in English.
One thousand and eighteen records were found (Fig-
ure 1). After excluding the duplicate records (n = 105)
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Page 2 of 12913 references remained. One reviewer (the first author)
assessed the relevance of the references. First, a selection
was made on title and/or abstract. Studies were included
if they examined effectiveness and/or cost-effectiveness
of lifestyle interventions targeting PA and eating habits
in persons with SMD. Studies were also included if par-
ticipants were adults aged 18 and over with a DSM-IV
diagnosis of schizophrenia, schizoaffective, depressive or
bipolar disorder or ‘severe mental disorder’ in general.
Furthermore, studies were included if the focus was on
changes in weight and BMI through the application of
psycho educational and/or behavioral interventions on
PA and/or eating habits.
Studies were excluded if they examined the effect on
weight and BMI of lifestyle interventions targeting PA
and eating habits in general populations. Studies were
also excluded if the primary outcome was not a mean
change in weight and BMI by the end of the interven-
tion. Studies examining the effect of a pharmacological
intervention on body weight and BMI without lifestyle
intervention were also excluded.
The selection based on title and/or abstract resulted in
34 references. Twelve additional references were found
by hand-searching the reference lists of the retrieved
articles from the electronic databases. Next, all non-sys-
tematic reviews (n = 5) were excluded, whereby 38 pri-
mary studies and three systematic reviews remained. As
we were only interested in randomized and non-rando-
mized controlled trials, all non-comparative trials (n =
11) were excluded. Full text of the remaining 27 primary
studies was then evaluated in detail on the above men-
tioned in- and exclusion criteria. Nine trials were
excluded. In two trials, participants were aged 15-44
years [43] and 16-50 years [44]. In three studies [45-47]
changes in body weight and BMI were not considered
as an outcome. In another study [48], changes in body
weight and BMI were secondary outcomes. Two trials
[49,50] reported no detailed data on changes in body
weight or BMI. Finally, in one trial [51] changes in
weight loss between persons with SMD and persons
without psychiatric problems were compared.
After this selection, 18 primary studies remained for
evaluation on quality. Study quality was assessed using a
checklist developed by the Cochrane Centre (Dutch ver-
s i o n )[ 5 2 ]a n dac h e c k l i s tf o rt h ea s s e s s m e n to ft h e
methodological quality of both randomized and non-
randomized studies of health care interventions [53].
Finally, 14 primary studies and three systematic
reviews were appropriate for this review.
Results
Three previous systematic reviews were identified
[54-56]. The review by Faulkner et al. [54] systematically
reviewed the literature of the effectiveness of interven-
tions designed to control weight gain in schizophrenia.
Sixteen studies met the inclusion criteria. Eight studies
consisted of pharmacological interventions, which was
an exclusion criterion for our review. The eight remain-
ing trials consisted of behavioral/dietary interventions.
Of these, two studies were also found by our electronic
search. One [49] was excluded (no data on changes in
BMI) and one [57] was included in our review. Six refer-
ences were not found by our search. Four of these were
conducted in the period before 1990 and consisted of
dietary restriction treatment. Another study of the per-
iod after 1990 also consisted of a dietary intervention
without behavioral intervention and one reference con-
sisted of a letter to the editor.
In another systematic review of Faulkner et al. [55] 23
randomized controlled trials were included. Eighteen
consisted of a pharmacological intervention, while the
five remaining studies consisted of a cognitive/beha-
vioral intervention. These five studies were also found in
our search.
The study by Lowe & Lubos [56] systematically
searched major databases for references about the effec-
tiveness of weight management interventions for people
with SMD receiving treatment with atypical antipsycho-
tics. All studies (n = 8) included in this review were also
found in our search. Six were included in our review.
Primary studies - Participants
The total number of participants in the selected studies
included 669 individuals (321 males, 328 females, 20 not
specified). Mean age of the participants was 39.7 years.
One study [58] provided no information about the mean
age of participants. The target group of eight studies con-
sisted of patients with schizophrenia or schizoaffective
disorder, in three trials of patients with schizophrenia, in
1018 articles found
Excluding duplicates (n=105)
913 articles remained
Selection on title/abstract (n=46)
Excluded studies (n=11)
Excluded reviews (n=5)
articles for full text evaluation
(27 trials; 3 systematic reviews)
Excluded articles after full text evaluation (n=9)
Excluded articles after quality appraisal (n=4)
17 articles included in review
(14 trials; 3 systematic reviews)
Figure 1 Search strategy.
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schizoaffective disorder, bipolar disorder or depression
and in one study the target group were patients with
bipolar disorder, schizoaffective disorder or depression.
One study provided no detailed information on DSM-IV
diagnosis of participants. The study population was
defined as ‘patients with mood or psychotic disorder’.I n
all studies, patients were treated with atypical antipsycho-
tics such as olanzapine, clozapine, rispiridone.
The total number of 669 participants consisted of 361
individuals in the intervention groups and 308 in the
control groups. Mean drop out rates were 20.6% (range
0.0 - 47.6%) in the intervention groups and 11.5% (range
0.0 - 33.3%) in the control groups. In three studies
[58-60], no drop outs were observed in the intervention
groups.
Nine studies recruited from outpatient settings, three
from inpatient settings and two from a combination of
both. Eight studies were conducted in the USA, while
the remaining were from Italy (n = 2), Australia (n = 1),
China (n = 1), Taiwan (n = 1), and South Korea (n = 1).
Primary studies - Design
Among the 14 included studies, 11 were randomized
controlled trials, while three were non-randomized con-
trolled trials (table 1). In eight trials, assessment of the
outcomes was made at baseline and endpoint, while in
six studies multi evaluation points were used. In eight
studies, assessment of the outcomes was based only on
participants who completed the intervention period (per
protocol). In the other six studies, outcome assessment
was based on data of all participants (intention to treat).
Primary studies - Weighing process
An analysis was performed to what extent information
about the weighing process (time of weighing, the use of
a weighing scale, clothing) was reported in the studies
included in the review. In eight studies, no details about
issues of the weighing process were described. Details
about the time of weighing were described in only four
studies [59-62]. In all of these four studies, participants
were weighed in the morning. In only one study, details
on the scale used for the weighing was described [63].
Two other studies reported that “t h es a m es c a l e ” (with-
out any details) was used. Details on the person(s) who
performed the measurement of weight and height was
described in three studies [58,62,63]. Information about
the clothing was reported in four studies: “without
shoes” [59,63], “in light clothing” [61], “wearing under-
wear” [62].
Primary studies - Interventions
We were interested in studies on psycho educational
and/or behavioral interventions on PA and/or eating
habits in persons with SMD. Seven studies consisted of
a psycho educational and/or behavioral intervention on
PA and/or dietary management. In the remaining seven
trials, the focus was not only on these kinds of interven-
tions, but also included supervised exercise (walking or
jogging). Topics on dietary management included educa-
tion and discussion on eating habits with emphasis on
energy intake/energy expenditure, and healthy eating.
Topics on PA management focused on assessment of
PA levels and discussion on changing activity levels and
adequate amounts of exercise. Intervention were group-
based (n = 4), individual (n = 3) or a combination of
both (n = 7).
The mean duration of the interventions was 20 ± 10.8
weeks (range 10-52 weeks). The study period was equal
to the duration of the health promotion intervention in
12 studies. In one study [64] the intervention period
was 12 weeks, while the study period lasted 24 weeks.
In another study [59] the intervention and study period
lasted respectively 16 and 24 weeks.
In two trials the control group also received the inter-
vention in a second phase of the study (cross-over
design). In one study [62], the control group received no
intervention from baseline until week nine. Afterwards,
a cross over was made, whereby the controls also
received the intervention between week nine and week
24. The study by Mauri et al. [63] had a similar design,
as the control group also received the intervention
between week 12 and week 24.
Primary studies - Results of the interventions
First, changes in body weight and BMI were analyzed in
intervention and control groups separately (table 2 &3).
In the intervention groups, weight loss was observed in
11 studies. This was statistically significant in five stu-
dies and not statistically significant in one study. For
five trials, no information on the level of significance of
weight loss was provided. Weight increase was observed
in three studies. In two studies [59,62], the increase was
not statistically significant. The study by Evans et al.[64]
provided no information on the level of significance of
weight increase in the intervention group.
In the control groups, a decrease in mean body weight
was reported in only four studies. This decrease was sta-
tistically significant in one study, not significant in
another and two trials provided no information on sig-
nificance of weight decline. In the other ten studies,
mean endpoint weight in controls increased (in three a
significant change, in one no significant change, and six
reported no information on significance).
In the intervention groups, a decrease in the mean
BMI was observed in 11 studies. The decrease was sta-
tistically significant in five of these trials. In one study
the decrease was not significant, while for five trials no
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Endpoint BMI was increased in two studies. In one trial,
this increase was not statistically significant, while the
other study reported no information on significance of
BMI increase. One study [62] provided no information
on mean endpoint BMI or changes in BMI neither in
intervention nor in control groups.
In the control groups, the mean BMI decreased in
only four studies (significant in one study, not signifi-
cant in another study and no information in the other
two). Mean BMI increased in nine trials. This increase
was significant in two studies, and not significant in one
study. No information on the level of significance was
available for the remaining six studies. Only one study
[65] reported confidence intervals around the changes in
weight or BMI.
Secondly, differences in changes in body weight and
BMI between the intervention and control groups were
analyzed (table 4). The difference in weight change
between intervention and control groups was statistically
significant in nine studies and not statistically significant
in five studies. Weighted average weight change based
on sample size in the intervention groups was -1.96 ±
1.84 kg (-1.74%) versus +1.77 ± 2.12 kg (+2.28%) in the
control groups. Differences in mean endpoint BMI
between intervention and control groups were statisti-
cally significant in eight studies and not significant in
three studies. In three trials, no information on signifi-
cant changes in BMI was reported. Weighted average
BMI change based on sample size in the intervention
groups was -0.87 ± 0.69 kg/m
2 versus +0.64 ± 0.96 kg/
m
2 in the control groups.
Table 1 Design of studies included in the review
author Design intervention study
period
intervention
period
individually/
group-based
Scocco et
al. [62]
randomized
controlled trial
intervention on providing information and assessment of dietary topics
compared to a control group not receiving intervention
24
weeks
8 weeks individually-
based
Evans et
al. [64]
randomized
controlled trial
intervention on education and setting specific goals on healthy eating and
lifestyle compared to a control group not receiving intervention
6
months
3 months individually-
based
Littrell et
al. [59]
randomized
controlled trial
intervention on providing information and prompting self-monitoring of
behavior on nutrition and exercise compared to a control group not
receiving intervention
6
months
16 weeks combination
Vreeland
et al. [68]
non-randomized
controlled trial
intervention on providing information and teaching on nutrition and healthy
living compared to a control group not receiving intervention
12
weeks
12 weeks combination
Weber &
Wyne [58]
randomized
controlled trial
intervention providing information and prompting self-monitoring of
behavior on nutrition and exercise compared to a control group not
receiving intervention
16
weeks
16 weeks group-based
McKibbin
et al. [61]
randomized
controlled trial
intervention on exercise and providing information and prompting self-
monitoring of behavior on nutrition and exercise compared to a control
group not receiving intervention
24
weeks
24 weeks group-based
Wu et al.
[65]
randomized
controlled trial
intervention on exercise and on providing information and prompting self-
monitoring of behavior compared to a control group not receiving
intervention
12
weeks
12 weeks combination
author Design intervention study
period
intervention
period
individually/
group-based
Mauri et
al. [63]
randomized
controlled trial
intervention on providing information and teaching on nutrition compared
to a control group receiving intervention in second study phase
24
weeks
12 weeks combination
Wu et al.
[60]
randomized
controlled trial
intervention on exercise and assessment of food and caloric intake compared
to a control group not receiving intervention
6
months
6 months combination
Ball et al.
[57]
non-randomized
controlled trial
intervention on exercise and on prompting self-monitoring of food choices
behaviour compared to a control group not receiving intervention
10
weeks
10 weeks combination
Skrinar et
al. [66]
randomized
controlled trial
intervention on exercise and providing information and prompting self-
monitoring of behavior on nutrition and wellness compared to a control
group not receiving intervention
12
weeks
12 weeks group-based
Kwon et
al. [67]
randomized
controlled trial
intervention on nutritional education and prompting self-monitoring of
dietary behavior and exercise compared to a control group not receiving
intervention
12
weeks
12 weeks individually-
based
Menza et
al. [69]
non-randomized
controlled trial
intervention on exercise and prompting self-monitoring of behavior on
nutrition and exercise compared to a control group not receiving
intervention
12
months
12 months combination
Brar et al.
[83]
randomized
controlled trial
intervention on teaching various behavioral techniques on nutrition and
exercise for weight loss compared to a control group not receiving
intervention
14
weeks
14 weeks group-based
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a follow up period during which the outcomes ‘weight’
and ‘BMI’ were also assessed. In the intervention group, a
significant increase in weight (+3.16 kg, p < .03) during
the follow up period of 12 weeks occurred in the study of
Scocco et al. [62]. In the study of Evans et al. [64] the
intervention group had not gained any further weight dur-
ing the follow up period of three months. A similar stable
mean body weight (follow up period of two months) was
reported by Littrell et al. [59]. In the trial of Mauri et al.
[63], weight loss occurred during the intervention period
(-3.6 kg), with a further weight loss during the 16-week
follow up period (-4.5 kg between baseline and endpoint).
Finally, differences in changes in body weight and BMI
between intervention and control groups were studied in
relation to the design of the intervention (individually,
group-based or a combination of both) and to the dura-
tion of the interventions.
Seven studies consisted of a combination of an indivi-
dual and a group-based intervention. In six of these stu-
dies significant changes in weight between intervention
and control groups were found. Furthermore, two of
three individual and one of four group-based
interventions produced statistically significant weight
changes between intervention and control groups. Simi-
lar results were found for changes in BMI between inter-
vention and control groups. Changes in BMI were
statistically significant in five of seven studies consisting
of a combination of an individual and group intervention.
A significant difference in changes in body weight and
BMI between intervention and control groups was
found in five of six trials with an intervention period of
12 weeks. In the two trials with an intervention period
of 24 weeks and one trial with an intervention period of
52 weeks, a significant difference in changes in body
weight and BMI was found.
Among the eight studies in which assessment of the
outcomes was based only on participants who com-
pleted the intervention period (per protocol), the differ-
ences in body weight and BMI between intervention
and control groups were statistically significant in only
four studies. In respectively five (body weight) and four
(BMI) of six studies, in which outcome assessment was
based on data of all participants (intention to treat), dif-
ferences between intervention and control groups were
statistically significant.
Table 2 Mean weight and BMI change from baseline to endpoint in intervention groups
author number baseline weight
(kg)
endpoint weight
(kg)
baseline BMI
(kg/m
2)
endpoint BMI
(kg/m
2)
changes in weight
(kg)
changes in BMI
(kg/m
2)
Scocco et al.
[62]
1
10 75,33 76,32 27,53 0,99
NS
Evans et al. [64] 29 82,80 84,80 28,80 29,50 2,00
NI 0,70
NI
Littrell et al.
[59]
35 81,12 81,49 26,26 26,39 0,37
NS 0,13
NS
Vreeland et al.
[68]
31 100,20 97,48 34,32 33,34 -2,72
NI -0,98
NI
Weber & Wyne
[58]
8 86,64 84,20 33,00 32,05 -2,44
NS -0,95
NS
McKibbin et al.
[61]
32 100,83 98,52 33,60 32,90 -2,31
NI -0,70
NI
Wu et al. [65] 32 64,70 63,40 24,60 23,10 -1,30 ** -1,50 **
Mauri et al. [63]
2
22 83,90 80,30 30,00 28,70 -3,60 ** -1,30 **
Wu et al. [60] 28 78,40 74,20 30,43 28,84 -4,20 * -1,59 *
Ball et al. [57] 21 107,91 105,60 36,90 36,20 -2,31
NI -0,70
NI
Skrinar et al.
[66]
15 97,10 94,90 32,90 32,30 -2,20
NI -0,60
NI
Kwon et al.
[67]
3
33 26,81 25,31 -3,94
NI -1,50
NI
Menza et al.
[69]
31 100,20 97,20 34,30 32,60 -3,00 ** -1,70 **
Brar et al. [83]
4 34 101,30 99,30 -2,00 ** -0,90 **
1Scocco et al. (2006): controls received intervention from week 9-24; results presented are the results after 8 weeks.
2Mauri et al. (2008): controls received intervention from week 12-24; results presented are the results after 12 weeks.
3Kwon et al. (2006): no information on baseline and endpoint weight, only on changes in weight.
4Brar et al. (2005): no information on baseline and endpoint BMI, only on changes in BMI.
*significant difference in weight or BMI change from baseline to endpoint in intervention groups (p < .001).
**significant difference in weight or BMI change from baseline to endpoint in intervention groups (p < .05).
Abbreviations: kg = kilogramme; BMI = Body Mass Index; NS = not significant; NI = no information on significance.
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Effects on QOL of psycho educational and behavioral
interventions targeting PA and eating habits were exam-
ined in five studies. Evans et al. [64] found a statistically
significant difference between intervention and control
group in subjective improvement of QOL (p = .047) and
in overall health (p = .023) as measured by the Clinical
Global Impressions (CGI). In the study by Mauri et al.
[63] the results of the Clinical Global Impressions Sever-
ity (CGI-S) in the total population showed a significant
improvement from baseline to endpoint (p < .05), while
no significant changes were shown for the Clinical Glo-
bal Impressions Improvement (CGI-I). No statistically
significant differences on the CGI-S and CGI-I were
observed between the intervention and control groups.
Furthermore, scores on the Quality of Life Enjoyment
and Satisfaction Questionnaire-Short Form (Q-LES-Q-
SF) significantly improved only in the control group (p
< .05).
The CGI-scale was also used in the study by Ball et al.
[57]. No statistically significant differences in CGI were
observed between baseline and endpoint of the interven-
tion. In the study by Skrinar et al. [66] only subjective
Table 3 Mean weight and BMI change from baseline to endpoint in control groups
author number baseline weight
(kg)
endpoint weight
(kg)
baseline BMI
(kg/m
2)
endpoint BMI
(kg/m
2)
changes in weight
(kg)
changes in BMI
(kg/m
2)
Scocco et al.
[62]
1
10 80,36 82,32 27,05 2,96 **
Evans et al. [64] 22 80,20 86,20 27,20 29,20 6,00
NI 2,00
NI
Littrell et al.
[59]
35 81,93 85,18 27,17 28,18 3,25 * 1,01 *
Vreeland et al.
[68]
15 93,62 96,52 33,40 34,60 2,90
NI 1,20
NI
Weber & Wyne
[58]
9 91,08 90,49 33,00 32,76 -0,59
NS -0,24
NS
McKibbin et al.
[61]
32 96,21 99,29 32,90 33,90 3,08
NI 1,00
NI
Wu et al. [65] 32 64,60 67,20 24,50 25,40 2,60 ** 0,90 **
Mauri et al. [63]
2
27 86,20 86,40 31,10 31,10 0,20
NS 0,00
NS
Wu et al. [60] 28 77,80 78,80 30,27 30,62 1,00
NI 0,35
NI
Ball et al. [57] 11 87,41 87,18 29,00 28,90 -0,23
NI -0,10
NI
Skrinar et al.
[66]
15 90,90 92,10 31,80 32,30 1,20
NI 0,50
NI
Kwon et al.
[67]
3
15 27,99 27,40 -1,48
NI -0,59
NI
Menza et al.
[69]
20 87,45 90,63 32,20 34,80 3,18
NI 2,60
NI
Brar et al. [83]
4 37 98,90 97,80 -1,10 ** -0,50 **
1Scocco et al. (2006): controls received intervention from week 9-24; results presented are the results after 8 weeks.
2Mauri et al. (2008): controls received intervention from week 12-24; results presented are the results after 12 weeks.
3Kwon et al. (2006): no information on baseline and endpoint weight, only on changes in weight.
4Brar et al. (2005): no information on baseline and endpoint BMI, only on changes in BMI.
*significant difference in weight or BMI change from baseline to endpoint in intervention groups (p < .001).
**significant difference in weight or BMI change from baseline to endpoint in intervention groups (p < .05).
Abbreviations: kg = kilogramme; BMI = Body Mass Index; NS = not significant; NI = no information on significance.
Table 4 Changes in weight and BMI between
intervention and control groups
author changes in
weight (kg)
changes in BMI
(kg/m
2)
Scocco et al. [62] -1,97
NS NI
Evans et al. [64] -4,00 ** -1,30 **
Littrell et al. [59] -2,88 ** -0,88
NI
Vreeland et al. [68] -5,62 ** -2,18 **
Weber & Wyne [58] -1,85
NS -0,71
NS
McKibbin et al. [61] -5,39 * -1,70 *
Wu et al. [65] -3,90 * -2,40 *
Mauri et al. [63] -3,80 ** -1,30 **
Wu et al. [60] -5,20 * -1,94 *
Ball et al. [57] -2,08
NS -0,60
NS
Skrinar et al. [66] -3,40
NS -1,10
NS
Kwon et al. [67] -2,46 ** -0,91 **
Menza et al. [69] -6,18 ** -4,30 **
Brar et al. [83] -0,90
NS -0,40
NI
*significant difference in weight or BMI change from baseline to endpoint in
intervention groups (p < .001).
**significant difference in weight or BMI change from baseline to endpoint in
intervention groups (p < .05).
Abbreviations: kg = kilogramme; BMI = Body Mass Index; NS = not significant;
NI = no information on significance.
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< .01) were significantly more improved in the interven-
tion group than in the control group. There was a statis-
tically non-significant improvement in health and well-
being from the Health Survey SF-36 and subscales from
the Lehman Quality of Life Questionnaire.
Finally, scores on psychological well-being, social rela-
tionship, and environmental domains did not show a
significant difference between the intervention and con-
trol group in the study by Kwon et al. [67]. There was
only a trend toward statistical difference in the physical
health score changes between the intervention and con-
trol group.
Primary studies - Cost-effectiveness of interventions
The cost-effectiveness of psycho educational, behavioral
and/or exercise interventions targeting PA and eating
habits in persons with SMD was examined in none of
the studies included in this review. Only in four studies,
there was a reference to topics of cost-effectiveness. In
their conclusion Vreeland et al. [68] and Menza et al.
[69] stated that cost-effectiveness of these kinds of inter-
ventions must be examined in further studies. Evans et
al.[64] concluded that further research is necessary to
investigate the most cost-effective ‘dose’ of intervention
required. Scocco et al. [62] emphasize the need for
further research in order to develop an efficacious
approach with an advantageous cost-benefit ratio.
Discussion
The results of this review demonstrate that small
improvements in body weight, BMI and QOL are possi-
ble through psycho educational and/or behavioral inter-
ventions targeting PA and/or eating habits in persons
with SMD.
In the intervention groups, weight loss and a decrease
of BMI is observed in 11 studies. In the control groups,
a decrease in mean body weight and BMI is reported in
only four studies. The difference in weight change
between intervention and control groups is statistically
significant in nine studies. Differences in mean endpoint
BMI between intervention and control groups are statis-
tically significant in eight studies.
Beside the significance of results it is also important to
give attention to the clinical relevance of these results.
According to the UK Department of Health [70] reduc-
tions in body weight of 5.0% or more are considered to
greatly reduce the risks of physical health problems. In
the included trials in our review, no study achieved this
target. Moreover, only in a limited number of studies
the weight loss resulted in changes of BMI classification
(e.g. from obesity to overweight or from overweight to
normal weight). In this sense, participants in the studies
included in the review may lose weight following a
lifestyle intervention but still remain in the overweight
or obesity class. It can thus be questioned to what
extent the BMI is useful to identify the risk for develop-
ing CVD. It appears that, according to the results of sev-
eral studies, the measurement of the waist
circumference and the waist-hip ratio is more appropri-
ate than measuring the BMI to estimate the risk for
future cardiovascular events [71,72]. It is important to
note that in all 14 trials participants were taking atypical
antipsychotics. It is well known that these drugs cause
weight gain [18]. Furthermore, there is conclusive evi-
dence that persons with SMD are more likely having
sedentary lifestyles, making poor dietary choices and are
more likely to smoke [21].
In eight studies included in the review, no information
was provided about the weighing process (time of
weighing, scale, clothing). The remaining six studies
provided, however not always detailed, information
about the weighing process. To minimize weighing
errors, patients should be weighed at the same time of
day using the same scale and in light clothing without
shoes [73]. Including this information in the methods
section of studies is important to enable an appropriate
assessment of the results. According to the results of a
study of weight measurement protocols no advantage
was found about measurement of weight on two sepa-
rate days compared with measurement on a single day
[74]. However, as far as we know, literature on this
topic is scarce and further studies evaluating weight
measurement procedures are required.
There are some limitations to acknowledge. For this
review, only references from the period 01/03/1990 until
01/03/2010 were included. In this way, it is possible that
we miss relevant papers from the period before 1990.
The trials included in this review are frequently lim-
ited in terms of small sample sizes, short intervention
periods and absence of long-term follow up. This raises
questions about the generalization of the results to
wider populations with mental disorders. In their review,
Lowe & Lubos[56] concluded that the current literature
on weight reduction interventions appears to provide
limited evidence on the effectiveness either of psycho
educational or of programs including educational and
exercise components. They also concluded that more
research is needed, with larger sample sizes as well as
standardized outcome measures to determine and com-
pare the effectiveness of these kinds of interventions.
The focus of the review considered ‘healthy living
interventions’ in persons with SMD. This created a
broad spectrum of ‘healthy living interventions’ topics
and approaches. From a research perspective it may
have been more appropriate only investigating one type
of intervention. However, people with SMD share many
risk factors, so it appears that general interventions will
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Page 8 of 12be more beneficial [75]. Weight management programs
through healthy eating, exercise and tobacco cessation
should be integrated into mental health care [76]. In
this sense, it was decided to include randomized and
non-randomized controlled trials with focus on health
promotion interventions targeting PA and eating habits
with primary outcomes changes in weight and BMI.
Beside ‘healthy living interventions’ also pharmacological
interventions to control weight gain in persons with MD
have been evaluated. In a review of pharmacological and
non-pharmacological interventions to control weight in
persons with schizophrenia, the authors concluded that
non-pharmacological interventions are preferable. The
promising results in the non-pharmacological studies
must however be tempered by weaker designs and small
sample sizes used in these studies [54]. According to the
results of a review on the mechanisms and management
of antipsychotic weight gain in schizophrenia, it was
concluded that pharmacological agents like orlistat and
sibutramine have not been sufficiently evaluated in anti-
psychotic weight gain [77]
Despite the limitations, it is promising that small
decreases of body weight and BMI in this population
are possible. It appears that health promotion interven-
tions targeting PA and eating habits in persons with
SMD may be useful for prevention of weight gain. It is
y e ti m p o r t a n tt on o t et h a tt h e r em a yb es o m ep a t i e n t s
(outliers) that may derive tremendous benefit, but that
the mean changes observed in the group are modest.
Categorical outcomes would enable the calculation of
the number needed to treat for the observation of a
clinically significant benefit for the intervention. Only
one study [65] reported confidence intervals around the
changes in weight or BMI. Data on confidence intervals
could however give insight in the ranges and thus in the
solidness of weight changes.
Furthermore, persons with mental health problems usually
want to learn more about healthy lifestyles and background
theories of lifestyle interventions [78,79]. In a study of per-
ceptions of barriers to and benefits of PA among patients
with SMD, participants saw exercise as positive and desir-
able, with benefits for both physical and mental health [80].
This suggests that persons with SMD are prepared to parti-
cipate in health promotion interventions.
Such findings support the integration of health pro-
motion interventions targeting PA and eating habits into
mental health care, whereby patients should be moti-
vated to follow these kinds of interventions. When
health promotion becomes a part of daily care, mental
health professionals could play an important role in
motivating their patients to participate. According to
patients’ perceptions mental health professionals can
provide support, motivation, and structure and they feel
comfortable with this support [81].
Elements of QOL were only investigated in five stu-
dies, providing no homogeneity of the effectiveness of
‘healthy living interventions’ on QOL and general health.
Yet, improvements in QOL were, although not always
statistically significant, observed. This is important
because weight gain is associated with perceptions of
poorer QOL and general health [82].
As far as known to the authors, this is the first sys-
tematic review of ‘healthy living interventions’ targeting
PA and eating habits in persons with SMD, in which
special attention was given if any of the included studies
also examined the cost-effectiveness of these interven-
tions. There is a growing need on health economic
research in health care and health policy. Especially,
attention is given to health economic evaluations of
medicines and technologies. Recently, more attention is
given to health economic evaluations of preventive
health care. In general populations, research on cost-
effectiveness of ‘healthy living interventions’ produces
no conclusive evidence [12,13], which is likely explained
by wide differences in program contents. In persons
with SMD, no studies examining the cost-effectiveness
of ‘healthy living interventions’ targeting PA and eating
habits were found. Yet, such research has a great social
value. Prevention has an economic cost, but it can also
save money because diseases and complications can be
avoided. Finally, prevention can produce healthy life
expectation.
Eight of 14 studies included in this review were con-
ducted in the USA. Because of differences in e.g. the
management of health care, health insurance systems,
and access to hospital care further studies, especially in
European countries examining both effectiveness and
cost-effectiveness of lifestyle interventions targeting PA
and eating habits in persons with SMD are required to
assist in the development of new health promotion
interventions in this population. Concerning cost-effec-
tiveness of interventions the viewpoint for the analysis
(e.g. point of view of society, the Ministry of Health, the
patient) should be carefully considered. Emphasis should
also be put on long-term effects of these kinds of
interventions.
Conclusions
This review demonstrated that, however not always sta-
tistically significant, small improvements in body weight,
BMI and QOL in persons with SMD are possible
through health promotion interventions targeting PA
and eating habits. In this sense, it appears to be relevant
to integrate these kinds of interventions into the daily
care of this population. Further research on both effec-
tiveness and cost-effectiveness of lifestyle interventions
on PA and eating habits in this population is required
to assist in the development of new health promotion
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Page 9 of 12interventions. Additional qualitative research on percep-
tions of health promotion of both mental health profes-
sionals and patients appears to be relevant. This
information can be useful when editing and implement-
ing lifestyle interventions on PA and eating habits in
mental health care.
Acknowledgements
none.
Author details
1Faculty of Medicine and Health Sciences, Ghent University, De Pintelaan 185
B-9000 Ghent, Belgium.
2Faculty of Medicine and Pharmacy, Vrije Universiteit
Brussel, Laarbeeklaan 103 B-1090 Brussel, Belgium.
Authors’ contributions
NV led the literature search strategy, retrieved, reviewed and assessed the
studies on study quality and developed the paper. LA and LM participated
in the design and coordination and helped to draft the manuscript, and
revised it critically for intellectual content. KVH and JDM revised the
manuscript critically for important intellectual content. All authors read and
approved the final manuscript
Competing interests
The authors declare that they have no competing interests.
Received: 8 July 2010 Accepted: 11 April 2011 Published: 11 April 2011
References
World Health Organization 2004. Obesity: preventing and managing the global
epidemic. Geneva, World Health Organization.
Cameron, AJ, TA Welborn, PZ Zimmet, DW Dunstan, N Owen, J Salmon, M
Dalton, D Jolley, and JE Shaw. 2003. Overweight and obesity in Australia: the
1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J
Aust 178(9): 427–432.
Sanchez, A, GJ Norman, JF Sallis, KJ Calfas, C Rock, and K Patrick. 2008. Patterns
and correlates of multiple risk behaviors in overweight women. Prev Med
46(3): 196–202. doi:10.1016/j.ypmed.2007.10.005.
World Health Organization 2004. Global strategy on diet, physical activity and
health. Geneva, World Health Organization.
Alwan, A, DR Maclean, LM Riley, ET d’Espaignet, CD Mathers, GA Stevens, and D
Bettcher. 2010. Monitoring and surveillance of chronic non-communicable
diseases: progress and capacity in high-burden countries. Lancet 376(9755):
1861–8. doi:10.1016/S0140-6736(10)61853-3.
Monteiro, CA, EC Moura, WL Conde, and BM Popkin. 2004. Socioeconomic status
and obesity in adult populations of developing countries: a review. Bull
World Health Organ 82(12): 940–946.
Clark, M, SE Hampson, L Avery, and R Simpson. 2004. Effects of a tailored lifestyle
self-management intervention in patients with type 2 diabetes. Br J Health
Psychol 9(Pt 3): 365–379. doi:10.1348/1359107041557066.
Eriksson, KM, CJ Westborg, and MC Eliasson. 2006. A randomized trial of lifestyle
intervention in primary healthcare for the modification of cardiovascular risk
factors. Scand J Public Health 34(5): 453–461. doi:10.1080/
14034940500489826.
Woo, J, MM Sea, P Tong, GT Ko, Z Lee, J Chan, and FC Chow. 2007. Effectiveness
of a lifestyle modification programme in weight maintenance in obese
subjects after cessation of treatment with Orlistat. J Eval Clin Pract 13(6):
853–859.
Annemans, L, M Lamotte, P Clarys, and E Van den Abeele. 2007. Health
economic evaluation of controlled and maintained physical exercise in the
prevention of cardiovascular and other prosperity diseases. Eur J Cardiovasc
Prev Rehabil 14(6): 815–824. doi:10.1097/HJR.0b013e3282ef514f.
Jacobs-van der Bruggen, MA, G Bos, WJ Bemelmans, RT Hoogenveen, SM Vijgen,
and CA Baan. 2007. Lifestyle interventions are cost-effective in people with
different levels of diabetes risk: results from a modeling study. Diabetes Care
30(1): 128–134. doi:10.2337/dc06-0690.
Roux, L, M Pratt, TO Tengs, MM Yore, TL Yanagawa, J Van Den Bos, C Rutt, RC
Brownson, KE Powell, G Heath, HW Kohl, S Teutsch, J Cawley, IM Lee, L West,
and DM Buchner. 2008. Cost effectiveness of community-based physical
activity interventions. Am J Prev Med 35(6): 578–588. doi:10.1016/j.
amepre.2008.06.040.
Muller-Riemenschneider, F, T Reinhold, and SN Willich. 2009. Cost-effectiveness of
interventions promoting physical activity. Br J Sports Med 43(1): 70–76.
doi:10.1136/bjsm.2008.053728.
Filik, R, A Sipos, PG Kehoe, T Burns, SJ Cooper, H Stevens, R Laugharne, G Young,
S Perrington, J McKendrick, D Stephenson, and G Harrison. 2006. The
cardiovascular and respiratory health of people with schizophrenia. Acta
Psychiatr Scand 113(4): 298–305. doi:10.1111/j.1600-0447.2006.00768.x.
Paton, C, R Esop, C Young, and D Taylor. 2004. Obesity, dyslipidaemias and
smoking in an inpatient population treated with antipsychotic drugs. Acta
Psychiatr Scand 110(4): 299–305. doi:10.1111/j.1600-0447.2004.00372.x.
Elmslie, JL, JT Silverstone, JI Mann, SM Williams, and SE Romans. 2000. Prevalence
of overweight and obesity in bipolar patients. J Clin Psychiatry 61(3):
179–184. doi:10.4088/JCP.v61n0306.
Dickerson, FB, CH Brown, JA Kreyenbuhl, L Fang, RW Goldberg, K Wohlheiter,
and LB Dixon. 2006. Obesity among individuals with serious mental illness.
Acta Psychiatr Scand 113(4): 306–313. doi:10.1111/j.1600-0447.2005.00637.x.
Parsons, B, DB Allison, A Loebel, K Williams, E Giller, S Romano, and C Siu. 2009.
Weight effects associated with antipsychotics: a comprehensive database
analysis. Schizophr Res 110(1-3): 103–110. doi:10.1016/j.schres.2008.09.025.
Brown, S, J Birtwistle, L Roe, and C Thompson. 1999. The unhealthy lifestyle of
people with schizophrenia. Psychol Med 29(3): 697–701. doi:10.1017/
S0033291798008186.
Osborn, DP, I Nazareth, and MB King. 2007. Physical activity, dietary habits and
Coronary Heart Disease risk factor knowledge amongst people with severe
mental illness: a cross sectional comparative study in primary care. Soc
Psychiatry Psychiatr Epidemiol 42(10): 787–793. doi:10.1007/s00127-007-0247-
3.
Henderson, DC, CP Borba, TB Daley, R Boxill, DD Nguyen, MA Culhane, P Louie, C
Cather, A Eden Evins, O Freudenreich, SM Taber, and DC Goff. 2006. Dietary
intake profile of patients with schizophrenia. Ann Clin Psychiatry 18(2):
99–105. doi:10.1080/10401230600614538.
McCreadie, RG. 2003. Diet, smoking and cardiovascular risk in people with
schizophrenia: descriptive study. Br J Psychiatry 183: 534–539. doi:10.1192/
bjp.183.6.534.
Roick, C, A Fritz-Wieacker, H Matschinger, D Heider, J Schindler, S Riedel-Heller,
and MC Angermeyer. 2007. Health habits of patients with schizophrenia. Soc
Psychiatry Psychiatr Epidemiol 42(4): 268–276. doi:10.1007/s00127-007-0164-5.
Chuang, HT, C Mansell, and SB Patten. 2008. Lifestyle characteristics of psychiatric
outpatients. Can J Psychiatry 53(4): 260–266.
Strassnig, M, JS Brar, and R Ganguli. 2003. Nutritional assessment of patients with
schizophrenia: a preliminary study. Schizophr Bull 29(2): 393–397.
Brown, S, H Inskip, and B Barraclough. 2000. Causes of the excess mortality of
schizophrenia. Br J Psychiatry 177: 212–217. doi:10.1192/bjp.177.3.212.
Fleischhacker, WW, M Cetkovich-Bakmas, HM De, CH Hennekens, M Lambert, S
Leucht, M Maj, RS McIntyre, D Naber, JW Newcomer, M Olfson, U Osby, N
Sartorius, and JA Lieberman. 2008. Comorbid somatic illnesses in patients
with severe mental disorders: clinical, policy, and research challenges. J Clin
Psychiatry 69(4): 514–519. doi:10.4088/JCP.v69n0401.
Lambert, TJ, D Velakoulis, and C Pantelis. 2003. Medical comorbidity in
schizophrenia. Med J Aust 178(Suppl): S67–S70.
Phelan, M, L Stradins, and S Morrison. 2001. Physical health of people with
severe mental illness. BMJ 322(7284): 443–444. doi:10.1136/bmj.322.7284.443.
Whyte, S, C Penny, M Phelan, J Hippisley-Cox, and A Majeed. 2007. Quality of
diabetes care in patients with schizophrenia and bipolar disorder: cross-
sectional study. Diabet Med 24(12): 1442–1448. doi:10.1111/j.1464-
5491.2007.02324.x.
Harris, EC, and B Barraclough. 1998. Excess mortality of mental disorder. Br J
Psychiatry 173: 11–53. doi:10.1192/bjp.173.1.11.
Dembling, BP, DT Chen, and L Vachon. 1999. Life expectancy and causes of
death in a population treated for serious mental illness. Psychiatr Serv 50(8):
1036–1042.
Miller, BJ, CB Paschall, and DP Svendsen. 2006. Mortality and medical
comorbidity among patients with serious mental illness. Psychiatr Serv
57(10): 1482–1487. doi:10.1176/appi.ps.57.10.1482.
Piatt, EE, MR Munetz, and C Ritter. 2010. An examination of premature mortality
among decedents with serious mental illness and those in the general
population. Psychiatr Serv 61(7): 663–668. doi:10.1176/appi.ps.61.7.663.
Verhaeghe et al. International Journal of Behavioral Nutrition and Physical Activity 2011, 8:28
http://www.ijbnpa.org/content/8/1/28
Page 10 of 12Daumit, GL, CB Anthony, DE Ford, M Fahey, EA Skinner, AF Lehman, W Hwang,
and DM Steinwachs. 2010. Pattern of mortality in a sample of Maryland
residents with severe mental illness. Psychiatry Res 176(2-3): 242–245.
doi:10.1016/j.psychres.2009.01.006.
Auquier, P, C Lancon, F Rouillon, and M Lader. 2007. Mortality in schizophrenia.
Pharmacoepidemiol Drug Saf 16(12): 1308–1312. doi:10.1002/pds.1496.
Brown, S. 1997. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry
171: 502–508. doi:10.1192/bjp.171.6.502.
Lawrence, DM, CD Holman, AV Jablensky, and MS Hobbs. 2003. Death rate from
ischaemic heart disease in Western Australian psychiatric patients 1980-1998.
Br J Psychiatry 182: 31–36. doi:10.1192/bjp.182.1.31.
Beebe, LH. 2008. Obesity in schizophrenia: screening, monitoring, and health
promotion. Perspect Psychiatr Care 44(1): 25–31. doi:10.1111/j.1744-
6163.2008.00144.x.
Casey, DE, DW Haupt, JW Newcomer, DC Henderson, MJ Sernyak, M Davidson,
JP Lindenmayer, SV Manoukian, MA Banerji, HE Lebovitz, and CH Hennekens.
2004. Antipsychotic-induced weight gain and metabolic abnormalities:
implications for increased mortality in patients with schizophrenia. J Clin
Psychiatry 65(Suppl 7): 4–18.
MacHaffie, S. 2002. Health promotion information: sources and significance for
those with serious and persistent mental illness. Arch Psychiatr Nurs 16(6):
263–274. doi:10.1053/apnu.2002.37281.
De Hert, M, JM Dekker, D Wood, KG Kahl, RI Holt, and HJ Moller. 2009.
Cardiovascular disease and diabetes in people with severe mental illness
position statement from the European Psychiatric Association (EPA),
supported by the European Association for the Study of Diabetes (EASD) and
the European Society of Cardiology (ESC). Eur Psychiatry 24(6): 412–424.
doi:10.1016/j.eurpsy.2009.01.005.
Alvarez-Jimenez, M, C Gonzalez-Blanch, JL Vazquez-Barquero, R Perez-Iglesias, O
Martinez-Garcia, T Perez-Pardal, ML Ramirez-Bonilla, and B Crespo-Facorro.
2006. Attenuation of antipsychotic-induced weight gain with early behavioral
intervention in drug-naive first-episode psychosis patients: A randomized
controlled trial. J Clin Psychiatry 67(8): 1253–1260. doi:10.4088/JCP.v67n0812.
Alvarez-Jimenez, M, O Martinez-Garcia, R Perez-Iglesias, ML Ramirez, JL Vazquez-
Barquero, and B Crespo-Facorro. 2010. Prevention of antipsychotic-induced
weight gain with early behavioural intervention in first-episode psychosis: 2-
year results of a randomized controlled trial. Schizophr Res 116(1): 16–19.
doi:10.1016/j.schres.2009.10.012.
Beebe, LH, L Tian, N Morris, A Goodwin, SS Allen, and J Kuldau. 2005. Effects of
exercise on mental and physical health parameters of persons with
schizophrenia. Issues Ment Health Nurs 26(6): 661–676. doi:10.1080/
01612840590959551.
Jean-Baptiste, M, C Tek, E Liskov, UR Chakunta, S Nicholls, AQ Hassan, KD
Brownell, and BE Wexler. 2007. A pilot study of a weight management
program with food provision in schizophrenia. Schizophr Res 96(1-3):
198–205. doi:10.1016/j.schres.2007.05.022.
McCreadie, RG, C Kelly, M Connolly, S Williams, G Baxter, M Lean, and JR
Paterson. 2005. Dietary improvement in people with schizophrenia:
randomised controlled trial. Br J Psychiatry 187: 346–351. doi:10.1192/
bjp.187.4.346.
Khazaal, Y, E Fresard, S Rabia, A Chatton, S Rothen, V Pomini, F Grasset, F
Borgeat, and D Zullino. 2007. Cognitive behavioural therapy for weight gain
associated with antipsychotic drugs. Schizophr Res 91(1-3): 169–177.
doi:10.1016/j.schres.2006.12.025.
Aquila, R, and M Emanuel. 2000. Interventions for Weight Gain in Adults Treated
With Novel Antipsychotics. Prim Care Companion J Clin Psychiatry 2(1):
20–23. doi:10.4088/PCC.v02n0106.
Melamed, Y, O Stein-Reisner, M Gelkopf, G Levi, T Sivan, G Ilievici, R Rosenberg, A
Weizman, and A Bleich. 2008. Multi-modal weight control intervention for
people with persistent mental disorders. Psychiatr Rehabil J 31(3): 194–200.
doi:10.2975/31.3.2008.194.200.
Skouroliakou, M, I Giannopoulou, C Kostara, and JC Hannon. 2009. Effects of
nutritional intervention on body weight and body composition of obese
psychiatric patients taking olanzapine. Nutrition 25(7-8): 729–735.
doi:10.1016/j.nut.2008.12.009.
Dutch Cochrane Centre 2009. Checklists en andere downloads. Amsterdam,
Dutch Cochrane Centre http://dcc.cochrane.org/beoordelingsformulieren-en-
andere-downloads.
Downs, SH, and N Black. 1998. The feasibility of creating a checklist for the
assessment of the methodological quality both of randomised and non-
randomised studies of health care interventions. J Epidemiol Community
Health 52(6): 377–384. doi:10.1136/jech.52.6.377.
Faulkner, G, AA Soundy, and K Lloyd. 2003. Schizophrenia and weight
management: a systematic review of interventions to control weight. Acta
Psychiatr Scand 108(5): 324–332. doi:10.1034/j.1600-0447.2003.00218.x.
Faulkner, G, T Cohn, and G Remington. 2007. Interventions to reduce weight
gain in schizophrenia. Cochrane Database Syst Rev , 1: CD005148.
Lowe, T, and E Lubos. 2008. Effectiveness of weight management interventions
for people with serious mental illness who receive treatment with atypical
antipsychotic medications. A literature review. J Psychiatr Ment Health Nurs
15(10): 857–863. doi:10.1111/j.1365-2850.2008.01337.x.
Ball, MP, VB Coons, and RW Buchanan. 2001. A program for treating olanzapine-
related weight gain. Psychiatr Serv 52(7): 967–969. doi:10.1176/appi.
ps.52.7.967.
Weber, M, and K Wyne. 2006. A cognitive/behavioral group intervention for
weight loss in patients treated with atypical antipsychotics. Schizophr Res
83(1): 95–101. doi:10.1016/j.schres.2006.01.008.
Littrell, KH, NM Hilligoss, CD Kirshner, RG Petty, and CG Johnson. 2003. The
effects of an educational intervention on antipsychotic-induced weight gain.
J Nurs Scholarsh 35(3): 237–241. doi:10.1111/j.1547-5069.2003.00237.x.
Wu, MK, CK Wang, YM Bai, CY Huang, and SD Lee. 2007. Outcomes of obese,
clozapine-treated inpatients with schizophrenia placed on a six-month diet
and physical activity program. Psychiatr Serv 58(4): 544–550. doi:10.1176/appi.
ps.58.4.544.
McKibbin, CL, TL Patterson, G Norman, K Patrick, H Jin, S Roesch, S Mudaliar, C
Barrio, K O’Hanlon, K Griver, A Sirkin, and DV Jeste. 2006. A lifestyle
intervention for older schizophrenia patients with diabetes mellitus: a
randomized controlled trial. Schizophr Res 86(1-3): 36–44. doi:10.1016/j.
schres.2006.05.010.
Scocco, P, R Longo, and F Caon. 2006. Weight change in treatment with
olanzapine and a psychoeducational approach. Eat Behav 7(2): 115–124.
Mauri, M, M Simoncini, S Castrogiovanni, N Iovieno, D Cecconi, G Dell’Agnello, M
Quadrigli, A Rossi, P Donda, A Fagiolini, and GB Cassano. 2008. A
psychoeducational program for weight loss in patients who have
experienced weight gain during antipsychotic treatment with olanzapine.
Pharmacopsychiatry 41(1): 17–23. doi:10.1055/s-2007-992148.
Evans, S, R Newton, and S Higgins. 2005. Nutritional intervention to prevent
weight gain in patients commenced on olanzapine: a randomized controlled
trial. Aust N Z J Psychiatry 39(6): 479–486.
Wu, RR, JP Zhao, H Jin, P Shao, MS Fang, XF Guo, YQ He, YJ Liu, JD Chen, and
LH Li. 2008. Lifestyle intervention and metformin for treatment of
antipsychotic-induced weight gain: a randomized controlled trial. JAMA
299(2): 185–193. doi:10.1001/jama.2007.56-b.
Skrinar, GS, NA Huxley, DS Hutchinson, E Menninger, and P Glew. 2005. The role
of a fitness intervention on people with serious psychiatric disabilities.
Psychiatr Rehabil J 29(2): 122–127. doi:10.2975/29.2005.122.127.
Kwon, JS, JS Choi, WM Bahk, KC Yoon, KC Hyung, SY Chul, BJ Park, and C Geun.
2006. Weight management program for treatment-emergent weight gain in
olanzapine-treated patients with schizophrenia or schizoaffective disorder: A
12-week randomized controlled clinical trial. J Clin Psychiatry 67(4): 547–553.
doi:10.4088/JCP.v67n0405.
Vreeland, B, S Minsky, M Menza, RD Rigassio, B Roemheld-Hamm, and R Stern.
2003. A program for managing weight gain associated with atypical
antipsychotics. Psychiatr Serv 54(8): 1155–1157. doi:10.1176/appi.ps.54.8.1155.
Menza, M, B Vreeland, S Minsky, M Gara, DR Radler, and M Sakowitz. 2004.
Managing atypical antipsychotic-associated weight gain: 12-month data on a
multimodal weight control program. J Clin Psychiatry 65(4): 471–477.
doi:10.4088/JCP.v65n0404.
Department of Health 2006. Care pathway for the management of overweight
and obesity.ed. Department of Health London . Department of Health
London.
Dalton, M, AJ Cameron, PZ Zimmet, JE Shaw, D Jolley, DW Dunstan, and TA
Welborn. 2003. Waist circumference, waist-hip ratio and body mass index
and their correlation with cardiovascular disease risk factors in Australian
adults. J Intern Med 254(6): 555–563. doi:10.1111/j.1365-2796.2003.01229.x.
Janssen, I, PT Katzmarzyk, and R Ross. 2004. Waist circumference and not body
mass index explains obesity-related health risk. Am J Clin Nutr 79(3):
379–384.
Collins, N, and L Friedrich. 2009. Why worry about body weight measurements?
Ostomy Wound Management 55(11): 16–19.
Verhaeghe et al. International Journal of Behavioral Nutrition and Physical Activity 2011, 8:28
http://www.ijbnpa.org/content/8/1/28
Page 11 of 12Maruthur, NM, WM Vollmer, JM Clark, GJ Jerome, LF Lien, CM Loria, and LJ
Appel. 2010. Measurement of weight in clinical trials: is one day enough?
J Obes.
Brown, S, and K Chan. 2006. A randomized controlled trial of a brief health
promotion intervention in a population with serious mental illness. Journal
of Mental Health 15(5): 543–549. doi:10.1080/09638230600902609.
Robson, D, and R Gray. 2007. Serious mental illness and physical health
problems: a discussion paper. Int J Nurs Stud 44(3): 457–466. doi:10.1016/j.
ijnurstu.2006.07.013.
Rege, S. 2008. Antipsychotic induced weight gain in schizophrenia:mechanisms
and management. Aust N Z J Psychiatry 42(5): 369–381. doi:10.1080/
00048670801961123.
Crone, D, and H Guy. 2008. ’I know it is only exercise, but to me it is something
that keeps me going’: a qualitative approach to understanding mental health
service users’ experiences of sports therapy. Int J Ment Health Nurs 17(3):
197–207. doi:10.1111/j.1447-0349.2008.00529.x.
Schmutte, T, E Flanagan, L Bedregal, P Ridgway, D Sells, T Styron, and L
Davidson. 2009. Self-efficacy and self-care: missing ingredients in health and
healthcare among adults with serious mental illnesses. Psychiatr Q 80(1): 1–8.
doi:10.1007/s11126-008-9088-9.
McDevitt, J, M Snyder, A Miller, and J Wilbur. 2006. Perceptions of barriers and
benefits to physical activity among outpatients in psychiatric rehabilitation. J
Nurs Scholarsh 38(1): 50–55. doi:10.1111/j.1547-5069.2006.00077.x.
Shiner, B, R Whitley, AD Van Citters, SI Pratt, and SJ Bartels. 2008. Learning what
matters for patients: qualitative evaluation of a health promotion program
for those with serious mental illness. Health Promot Int 23(3): 275–282.
doi:10.1093/heapro/dan018.
Allison, DB, JA Mackell, and DD McDonnell. 2003. The impact of weight gain on
quality of life among persons with schizophrenia. Psychiatr Serv 54(4):
565–567. doi:10.1176/appi.ps.54.4.565.
Brar, JS, R Ganguli, G Pandina, I Turkoz, S Berry, and R Mahmoud. 2005. Effects of
behavioral therapy on weight loss in overweight and obese patients with
schizophrenia or schizoaffective disorder. J Clin Psychiatry 66(2): 205–212.
doi:10.4088/JCP.v66n0208.
doi:10.1186/1479-5868-8-28
Cite this article as: Verhaeghe et al.: Effectiveness and cost-effectiveness
of lifestyle interventions on physical activity and eating habits in
persons with severe mental disorders: A systematic review. International
Journal of Behavioral Nutrition and Physical Activity 2011 8:28.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Verhaeghe et al. International Journal of Behavioral Nutrition and Physical Activity 2011, 8:28
http://www.ijbnpa.org/content/8/1/28
Page 12 of 12